Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 183-192 , April 2010

Adverse effects of drugs in the treatment of viral hepatitis

  • Francesco Negro (Professor)

      Affiliations

    • Divisions of Clinical Pathology, University Hospitals, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland
    • Divisions of Gastroenterology and Hepatology, University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1211 Geneva 14, Switzerland
    • Corresponding Author InformationDivision of Clinical Pathology, Centre Médical Universitaire, 1 rue Michel-Servet, 1206 Geneva, Switzerland. Tel.: +41 22 3795800; fax: +41 22 3729366.

References 

  1. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol. 2008;22:991–1008
  2. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711–1719
  3. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38–47
  4. Marcellin P, Heathcote EJ, Craxì A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?. J Hepatol. 2007;47:580–587
  5. Ria R, Gasparre T, Mangialardi G, Bruno A, Iodice G, Vacca A, et al. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant. 2009 Jul 6;[Epub ahead of print]
  6. Yamane A, Nakamura T, Suzuki H, Ito M, Ohnishi Y, Ikeda Y, et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood. 2008;112:542–550
  7. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol. 1996;25:972–975
  8. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227–2236
  9. Forton DM, Taylor-Robinson SD, Thomas HC. Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2006;18:333–338
  10. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry. 2004;26:237–240
  11. Kraus MR, Schäfer A, Schöttker K, Keicher C, Weissbrich B, Hofbauer I, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008;57:531–536
  12. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1994;89:399–403
  13. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology. 1997;26:206–210
  14. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993;18:253–257
  15. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf). 1996;44:635–642
  16. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alphainterferon therapy for chronic viral hepatitis. J Hepatol. 1998;28:514–517
  17. Descamps V. Cutaneous side effects of alpha interferon. Presse Med. 2005;34:1668–1672
  18. Lübbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol. 2005;153:1088–1090
  19. Berk DR, Mallory SB, Keeffe EB, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol. 2007;5:142–151
  20. Kanazawa K, Yaoita H, Tsuda F, Murata K, Okamoto H. Association of prurigo with hepatitis C virus infection. Arch Dermatol. 1995;131:852–853
  21. Lang AM, Norland AM, Schuneman RL, Tope WD. Localized interferon alfa-2b-induced alopecia. Arch Dermatol. 1999;135:1126–1128
  22. Khella SL, Frost S, Hermann GA, Leventhal L, Whyatt S, Sajid MA, et al. Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy. Treatment with interferon alfa: case report and literature review. Neurology. 1995;45:407–411
  23. Stübgen JP. Interferon alpha and neuromuscular disorders. J Neuroimmunol. 2009;207:3–17
  24. Weegink CJ, Chamuleau RA, Reesink HW, Molenaar DS. Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin. J Gastroenterol. 2001;36:723–724
  25. Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci. 2001;322:233–235
  26. Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol. 2001;85:1171–1173
  27. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31:997–1004
  28. Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007;46:371–379
  29. Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, Collantes R, et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat. 2008;15:370–378
  30. Tseng KC, Chen LH, Chen CY, Chang TT, Chou AL, Wu IC, et al. Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b. Hepatol Res. 2009;39:539–545
  31. McHutchison JG, Manns MP, Brown RS, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol. 2007;102:880–889
  32. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450
  33. Lebray P, Nalpas B, Vallet-Pichard A, Broissand C, Sobesky R, Serpaggi J, et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antiviral Ther. 2005;10:769–77638–50
  34. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to the treatment for the hepatitis C virus. Hepatology. 2007;46:37–47
  35. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology. 2006;44:1400–1403
  36. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  37. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485–1492
  38. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147:1142–1146
  39. Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology. 2008;48:407–417
  40. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850
  41. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838
  42. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PEG-Intron (peginterferon alfa-2b)/ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C. J Hepatol. 2009;50(Suppl. 1):S4
  43. Crabbé R, Vuagniaux G, Dumont JM, Nicolas-Métral V, Marfurt J, Novaroli L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs. 2009;18:211–220
  44. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology. 2009;49:1460–1468
  45. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–1722
  46. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
  47. http://www.emea.europa.eu/humandocs/Humans/EPAR/baraclude/baraclude.htm2009;[accessed on July 24.07.09]
  48. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009 May 6;[Epub ahead of print]

PII: S1521-6918(09)00161-9

doi: 10.1016/j.bpg.2009.10.012

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 183-192 , April 2010

Article Tools